Print page content Print
Increase text size Decrease text size
Text Size

This site is intended for U.S. animal healthcare professionals


This site is intended for U.S. animal healthcare professionals

Remy and Debbie

CYTOPOINT® makes a meaningful difference in the lives of pet owners, veterinarians and dogs with allergic itch

CYTOPOINT provides pet owners with relief from stress caused by their dogs’ allergic itch1

  • CYTOPOINT provided lasting control of allergic itch2
  • Effective and long-lasting control of chronic diseases such as allergic dermatitis lessens pet owner anxiety by restoring a household’s normal routine1
  • Significant improvement in owner quality of life* was directly correlated with reduction in a dog’s atopic itch3

The Canine Dermatitis Quality of Life (QoL) instrument measured dog QoL, dog owner QoL and treatment satisfaction.

Owners value the long-lasting efficacy, safety and convenience of in-office CYTOPOINT injections4

Dog owners are highly satisfied with CYTOPOINT4

  • The majority of owners said that they will definitely continue treatment with CYTOPOINT for their dog

Lasting relief achieved through compliance and collaboration

  • Pet owners are 7 times more likely to follow a treatment plan following a clear recommendation rather than those given an ambiguous recommendation2
  • CYTOPOINT presents an opportunity for more practice visits and a better opportunity to monitor treatment response5
    • 10 visits per year versus 7 visits per year before using CYTOPOINT

Owners had less to juggle when CYTOPOINT was given as a monotherapy6

  • Most dogs needed fewer concomitant medications such as steroids, antibiotics, topical ointments, shampoos, hypoallergenic diets, etc.5
    • Concomitant medications can increase stress felt by owners and lead to non-compliance

CYTOPOINT is a safe choice for dogs with allergic itch

CYTOPOINT was shown to be safe and effective in an independent, real-world study of dogs with allergic dermatitis1

  • Safe to use in dogs of any age
  • There are no known drug interactions with CYTOPOINT—safe in combination with other medications including7:
    • APOQUEL® (oclacitinib tablet), corticosteroids, cyclosporine and antihistamines
    • Treatments such as parasiticides, antibiotics, antifungals, vaccines, NSAIDs and allergen-specific immunotherapy

Adverse events reported in >2% of dogs in a field safety study7‡

adverse events graph

Other than pruritus and alopecia, which were substantially more common in dogs receiving placebo.

Occurrence calculated on a per-case basis—no matter how many observations of the same abnormal health event a dog had, it contributed one observation to the occurrence calculation.

See real stories of lasting relief

Dublin’s owner needed convenient treatment administration8

He is back to being that fun-loving dog...I know that he’s going to be OK. And that peace of mind is literally priceless.”

SherryAnn Quindley, Dublin’s owner

Dublin's story

Sophie needed to get back to work as a therapy dog8

To see her be pain free and not irritated...has been a profound relief for me. It's a comfort to know that those days are behind her.”

Rick Sirianni, Sophie’s owner

Sophie's story

Exeland required treatment that worked with his comorbidities8

This [product] truly saved both [the owner's] and my patient's lives! I don't know what I would have done without having access to this amazing [product]. Thank you Zoetis!”

Dr Lisa Reiter, Exeland’s DVM

Exeland's story

Harley's owner needed an alternative to pilling8

Harley's owner seemed very happy at the one-month recheck. It seemed like we had taken a weight off of her shoulders in terms of having to administer medication at home.”

Dr Liz Hardesty, Harley’s DVM

Harley's story

Indications: CYTOPOINT has been shown to be effective for the treatment of dogs against allergic dermatitis and atopic dermatitis.

APOQUEL Indications: Control of pruritus associated with allergic dermatitis and control of atopic dermatitis in dogs at least 12 months of age.

APOQUEL Important Safety Information: Do not use APOQUEL in dogs less than 12 months of age or those with serious infections. APOQUEL may increase the chances of developing serious infections, and may cause existing parasitic skin infestations or pre-existing cancers to get worse. APOQUEL has not been tested in dogs receiving some medications including some commonly used to treat skin conditions such as corticosteroids and cyclosporine. Do not use in breeding, pregnant, or lactating dogs. Most common side effects are vomiting and diarrhea. APOQUEL has been used safely with many common medications including parasiticides, antibiotics and vaccines.

For more information, please see the full Prescribing Information.

References: 1. Spitznagel MB, Cox MD, Jacobson DM, et al. Assessment of caregiver burden and associations with psychosocial function, veterinary service use, and factors related to treatment plan adherence among owners of dogs and cats. J Am Vet Med Assoc. 2019;254(1):124-132. doi:10.2460/javma.254.1.124. 2. Souza C, Rosychuk RAW, Contreras E, et al. A retrospective analysis of the use of lokivetmab in the management of allergic pruritus in a referral population of 135 dogs in the western USA. Vet Dermatol. 2018. doi:10.1111/vde.12682. 3. Data on file, Quality of Life Outcomes Research, 2018, Zoetis Inc. 4. Data on file, APOQUEL/CYTOPOINT Pet Tracker Wave 5, 2017, Zoetis Inc. 5. Data on file, Study No. 16SORDER0101, 2017, Zoetis Inc. 6. Data on file, APOQUEL/CYTOPOINT Vet Tracker Wave 9, 2018, Zoetis Inc. 7. Data on file, Study Report No. C961R-US-13-051, 2014, Zoetis Inc. 8. Data on file, CYTOPOINT Case Studies, Zoetis Inc.

This site is intended for U.S. Animal Healthcare Professionals. The animal health information contained herein is provided for educational purposes only and is not intended to replace discussions with an animal healthcare professional. All decisions regarding the care of a veterinary patient must be made with an animal healthcare professional, considering the unique characteristics of the patient.

The product information provided in this site is intended only for residents of the United States. The products discussed herein may not have marketing authorization or may have different product labeling in different countries. 

All trademarks are the property of Zoetis Services LLC or a related company or a licensor unless otherwise noted.
© 2020 Zoetis Services LLC. All rights reserved. CYT-00090R5



We are Mon–Fri, 8:30am–8:00pm ET

This site is intended for U.S. Animal Healthcare Professionals.

All trademarks are the property of Zoetis Services LLC or a related company or a licensor unless otherwise noted. ©2020 Zoetis Services LLC. All rights reserved.